Dashboard
Poor Management Efficiency with a low ROE of 0%
- The company has reported losses. Due to this company has reported negative ROE
Poor long term growth as Net Sales has grown by an annual rate of -3.35% and Operating profit at -452.20% over the last 5 years
Negative results in Jun 25
Risky - Negative EBITDA
Consistent Underperformance against the benchmark over the last 3 years
Stock DNA
Pharmaceuticals & Biotechnology
JPY 3,759 Million (Micro Cap)
NA (Loss Making)
NA
0.00%
-0.94
-56.73%
1.52
Total Returns (Price + Dividend) 
FunPep Co., Ltd. for the last several years.
Risk Adjusted Returns v/s 
News

FunPep Co., Ltd. Faces Significant Challenges Amidst Deteriorating Financial Performance
FunPep Co., Ltd. has experienced a significant evaluation adjustment, moving from 'Not Rated' to 'Strong Sell.' The company faces challenges, including a low return on equity and declining net sales and profits, indicating ongoing underperformance and concerns about its long-term viability in the Pharmaceuticals & Biotechnology sector.
Read More Announcements 
Corporate Actions 
Quality key factors 
Valuation key factors
Technicals key factors
Shareholding Snapshot
Shareholding Compare (%holding) 
Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ
QoQ Growth in quarter ended Jun 2025 is -100.00% vs -96.15% in Mar 2025
QoQ Growth in quarter ended Jun 2025 is 50.55% vs -81.77% in Mar 2025
Annual Results Snapshot (Consolidated) - Dec'24
YoY Growth in year ended Dec 2024 is 1,120.00% vs -54.55% in Dec 2023
YoY Growth in year ended Dec 2024 is 4.75% vs 20.39% in Dec 2023






